Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000953622 | SCV001100201 | likely benign | not provided | 2018-08-08 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004029848 | SCV003684568 | uncertain significance | not specified | 2021-11-03 | criteria provided, single submitter | clinical testing | The c.112A>G (p.I38V) alteration is located in exon 2 (coding exon 2) of the TNMD gene. This alteration results from a A to G substitution at nucleotide position 112, causing the isoleucine (I) at amino acid position 38 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV000953622 | SCV005210709 | likely benign | not provided | criteria provided, single submitter | not provided |